Expect a Limited Role for Colchicine in Reducing CV Risk

November 2023

You’ll get questions about the role of new Rx colchicine (Lodoco) for patients with chronic coronary disease.

There’s been growing interest in using colchicine to reduce CV risk...due to its anti-inflammatory effect.

Lodoco is the same drug we use for gout...but it’s 0.5 mg instead of 0.6 mg. And it’s the first colchicine approved to reduce CV risk.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote